紫杉醇脂质体和多西他赛用于乳腺癌新辅助化疗的效果及安全性比较

Comparison of Effect and Safety of Paclitaxel Liposome and Docetaxel in Neoadjuvant Chemotherapy for Breast Cancer

目的:探讨紫杉醇脂质体和多西他赛用于乳腺癌新辅助化疗的效果及安全性比较。方法:选取2018年1-12月邳州市人民医院收治的200例乳腺癌患者,按照电脑随机分组法将患者分为两组。观察组100例患者采用紫杉醇脂质体、表柔比星和环磷酰胺治疗,对照组100例患者采用多西他赛、表柔比星和环磷酰胺治疗。比较两组总有效率及不良反应发生情况。结果:观察组总有效率为74.00%,高于对照组的46.00%,差异有统计学意义(P<0.05)。两组中性粒细胞减少、白细胞计数减少、血小板减少、血红蛋白减少、腹泻、恶心呕吐的发生率比较,差异均无统计学意义(P>0.05)。结论:在乳腺癌新辅助化疗中应用紫杉醇脂质体对提高治疗效果有较好的帮助,不增加药物不良反应,具有临床借鉴意义。

Objective:To compare the effect and safety of Paclitaxel Liposome and Docetaxel in neoadjuvant chemotherapy for breast cancer.Method:A total of 200 breast cancer patients admitted to the People’s Hospital of Pizhou from January 2018 to December 2018 were selected,they were divided into two groups according to the computer randomization method.One hundred patients in the observation group were treated with Paclitaxel Liposomes,Epirubicin and Cyclophosphamide.One hundred patients in the control group were treated with Docetaxel,Epirubicin and Cyclophosphamide.The total effective rate and the occurrence of adverse reactions were compared between two groups.Result:The total effective rate of observation group was 74.00%,which was higher than 46.00% of control group,the difference was statistically significant (P<0.05).There were no significant differences in the incidence of neutropenia,leukopenia,thrombocytopenia,hemoglobin reduction,diarrhea,nausea and vomiting between two groups (P>0.05).Conclusion:The application of Paclitaxel Liposomes in neoadjuvant chemotherapy for breast cancer can improve the therapeutic effect without increasing the adverse reactions of the drug,which has clinical reference significance.